The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified
Modern Pathology · 2023
DOI: 10.1016/j.modpat.2023.100349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Lianqun Qiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Laboratory Medicine and Pathology, Un…. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
A small subset of high-grade B-cell lymphoma (HGBL) with blastoid morphology remains poorly understood. We assessed 55 cases of blastoid HGBL, not otherwise specified (NOS) and compared their clinicopathologic characteristics with those of 81 non-blastoid HGBL-NOS and 62 blastoid HGBL with MYC and BCL2, with or without BCL6 rearrangements (double/triple-hit lymphoma [D/THL]). Patients with blastoid HGBL-NOS showed similar clinicopathologic features to patients with blastoid D/THLs and non-blastoid HGBL-NOS, except more frequently with a history of low-grade B-cell lymphoma, bone marrow involvement, and BCL2 rearrangement (P < .05) compared to the latter. MYC rearrangement (MYC-R), detected in 40% of blastoid HGBL-NOS, was associated with aggressive clinicopathologic features and poorer overall survival, even worse than that of blastoid D/THL (P < .05). Transcriptome profiling revealed a distinct gene expression pattern with differentially expressed genes enriched in MYC and P53-targeted genes in MYC-R blastoid HGBL-NOS. Fifty-two percent of blastoid HGBL-NOS had a double hit-like signature, similar to non-blastoid HGBL-NOS (P = .73). The overall survival of the blastoid HGBL-NOS group was similar to that of the blastoid D/THL group but appeared poorer than that of its non-blastoid counterparts (P = .07). Taken together, blastoid HGBL-NOS is an aggressive B-cell lymphoma that shares overlapping clinicopathologic and genetic features with non-blastoid HGBL-NOS. MYC-R in patients with blastoid HGBL-NOS identifies a highly aggressive subgroup with distinct aggressive clinicopathologic features, unique molecular signatures, and a dismal clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. Electronic address: qiulq…
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: SLi6@mdanderson.org.
Förderung
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Qiu, L., Lin, P., Khanlari, M., Xu, J., Cohen, E. N., Garces, S., Miranda, R. N., Wang, W., Fang, H., Bueso-Ramos, C. E., Medeiros, L. J., & Li, S. (2023). The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100349
Vancouver
Qiu L, Lin P, Khanlari M, Xu J, Cohen EN, Garces S, et al. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100349
BibTeX
@article{Qiu2023,
author = {Qiu, Lianqun and Lin, Pei and Khanlari, Mahsa and Xu, Jie and Cohen, Evan N and Garces, Sofia and Miranda, Roberto N and Wang, Wei and Fang, Hong and Bueso-Ramos, Carlos E and Medeiros, L Jeffrey and Li, Shaoying},
title = {The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified},
journal = {Modern Pathology},
year = {2023},
doi = {10.1016/j.modpat.2023.100349}
}
EUVIMED